GRI

Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids

News Healthcare & Pharma Guidance
Date: 15th Nov, 2024 Source: European Medicines Agency (EMA) Country: European Union Original Source

Brief

On "15/11/2024", the "European Medicines Agency (EMA)" issued an update regarding "Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids". The EMA recommends updating the advice on minimising the risks of interaction between Mysimba, a weight loss medicine, and opioid-containing medicines. This is due to concerns that Mysimba may not work effectively in patients taking opioids and may increase the risk of rare but serious reactions such as seizures and serotonin syndrome.

This content is restricted.

Highlights content goes here...

This content is restricted.

European Medicines Agency (EMA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
Related Documents
Siemens Industrial Edge Devices
Date: 10th Apr, 2025 Source: Cybersecurity and Infrastructure Security Agency Country: USA
News Cybersecurity Guidance
Siemens Insights Hub Private Cloud
Date: 10th Apr, 2025 Source: Cybersecurity and Infrastructure Security Agency Country: USA
News Cybersecurity Guidance
handelsfusion.com: BaFin warns of website and points to suspected identity fraud
Date: 10th Apr, 2025 Source: Federal Financial Supervisory Authority (BaFin) Country: Germany
News Corporate Finance & M&A Guidance

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Click here

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
  • Designed for Growing Compliance Teams
$125 / month OR $1250 / year
Features
  • • Coverage for 20 jurisdictions
  • • Monitoring from 500+ regulatory authorities
  • • AI compliance summaries
  • • RaDa.ai : Single-Role
Best for: Researchers, Legal professionals, Academics
Subscribe Now
Enterprise Plan
  • Perfect for Global Enterprises
Contact for Pricing
Features
  • • Custom jurisdictional coverage
  • • Custom monitoring of regulatory authorities
  • • RaDa.ai : Customizable multi-role
  • • Custom reporting and dashboard capabilities
  • • API access for seamless integration
Best for: Law Firms, Corporations, Government Bodies
Contact Sales